Latent Labs

Rounds and research, on one timeline

1. 2026-07-15
   Research

   Level 4 · Tested in the physical world

   Latent Labs opens Latent-Y, an agent that designs antibodies from a written prompt, to any approved researcher

   This is the step from a model a protein designer drives to one that makes the design decisions, and the test is who can use it. The launch release names three outside groups that got lab-validated designs, including a UC Davis lab that blocked a human ion channel with four of five designed nanobodies, and says some had no computational design experience. Those outside results are Latent Labs' own account; the 6-of-9 figure is its own wet lab.

   Timeline entry →latentlabs.com ↗

2. 2025-12-23
   Research

   Level 4 · Tested in the physical world

   Latent Labs designs antibodies from scratch that bind 9 of 18 targets; four designed against one of them raise no detectable immune response in ten donors' cells

   Immunogenicity is one of the reasons antibodies fail in the clinic, and the authors say nobody had measured it on an AI-designed antibody before. Four VHHs designed against one target, TNFL9, were put on immune cells from ten healthy donors: no detectable T-cell proliferation and no detectable cytokine release, a profile the paper calls comparable to caplacizumab, an approved VHH drug. Donor cells in a dish are a proxy; no animal or human data exists yet.

   Timeline entry →arxiv.org ↗

3. 2025-07-25
   Research

   Level 4 · Tested in the physical world

   Latent Labs' binder model hits 91-100% lab hit rates on three macrocycle targets, from 11 to 17 molecules assayed each

   A hit rate that high changes what a design round costs: tens of molecules to make and assay instead of thousands, which is the step where a generative model meets a bench budget. Latent Labs chose the designs and set the thresholds; GenScript ran the binding assays, and the specificity check was in-house. Its comparison takes the rivals' hit rates from their papers and remeasures only their best binders, where its own replication disagrees sharply with the published numbers, and Latent-X does not lead on every target. No peer review and no outside lab has repeated it.

   Timeline entry →arxiv.org ↗

4. 2025-02-13Series A
   Round

   $40M

   For: its generative protein design models and partnerships

   Models and platformCommercial roll-out

   Announced on leaving stealth with $50M in total funding: this $40M Series A plus the $10M seed disclosed at the same time.

   Co-lead · Radical Ventures ✓Co-lead · Sofinnova Partners ✓Flying Fish ✓Isomer ✓8VC ✓Kindred Capital ✓Pillar VC ✓Jeff Dean (angel)Aidan GomezMati Staniszewski

   On the deal: Aaron Rosenberg (Partner, Radical Ventures); Aidan Gomez (Angel investor); Edward Kliphuis (Partner, Sofinnova Partners); Jeff Dean (Angel investor); Mati Staniszewski (Angel investor)

   The investor's own page says · Flying Fish: 2025

   The investor's own page says · Radical Ventures: 2024

   Announced by the company · latentlabs.com ↗

5. 2025-02-13date disclosed · close date not givenSeed
   Round

   $10M

   Not stated

   First disclosed in the Series A announcement, where TechCrunch, with the founder on record, calls it a previously unannounced $10M seed tranche; its date was not given. Pillar's own post (pillar.vc/startups/investing-in-latent-labs) says it co-led the seed with Kindred.

   Co-lead · Pillar VC ✓Co-lead · Kindred Capital ✓

   The investor's own page says · Flying Fish: 2025

   The investor's own page says · Radical Ventures: 2024

   Announced by the company · techcrunch.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →